EcoR1 Capital — 2018 Investments

5 investments dated 2018 · listed companies and verified rows first · show all

Anaginanagin.com inJun 2018

A drug discovery company focused on medicinal chemistry and preclinical research across multiple therapeutic areas.

BiotechDigital HealthHealthtechMedical DevicesMental HealthIndianapolis, US

Jaswant Gidda(Executive Officer, Director)inJames Schulz(Executive Officer)Yvonne Lai(Executive Officer)

BoardNora Doherty(Director)Derek Small(Director)Anantha Shekhar(Director)

Nabriva Therapeuticsnabriva.comJul 2018

BiotechDublin 1

Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)

Co-investorsAisling Capital Frazier Life Sciences Longitude Capital MESA VERDE VENTURE PARTNERS Novartis Venture Fund

Unity Biotechnologyunitybiotechnology.com inMar 2018Defunct

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsage1 Alumni Ventures ARCH Venture Partners Cycad Group LLC Khosla Ventures Venrock +6 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Magenta Therapeutics Prevail Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.